Psylo is a drug development company focused on next generation psychedelics; our goal is to make broadly accessible medicines as improved treatments to currently available SSRI medications, using psychedelic molecules as the starting point. We are building a pipeline of novel molecules with the ultimate goal of taking leading candidates through to clinical trials.
Location: Australia, New South Wales, Sydney
Employees: 1-10
Total raised: $13M
Investors 3
| Date | Name | Website |
| - | Empath Ven... | empath.vc |
| - | Tenmile | tenmile.co... |
| 15.11.2022 | Main Seque... | mseq.vc/ |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.06.2024 | Seed | $8M | - |
| 27.10.2022 | Seed | $5M | - |
Mentions in press and media 8
| Date | Title | Description |
| 29.10.2024 | New Frontiers in Health Research: Tackling Addiction and Intersex Health | In a world where health challenges loom large, two groundbreaking initiatives emerge from the University of Sydney. One aims to tackle the complex web of addiction, while the other seeks to illuminate the often-overlooked health needs of in... |
| 29.10.2024 | $3M GRANT TO ACCELERATE DEVELOPMENT OF NEUROPLASTOGENS FOR SUBSTANCE USE DISORDER TREATMENT | CRC-P GRANT SECURED BY TESSARA THERAPEUTICS, PSYLO, AND THE UNIVERSITY OF SYDNEY TO ADVANCE BRAIN-REWIRING TREATMENTS FOR ADDICTION BOULDER, Colo., Oct. 29, 2024 /PRNewswire/ -- Tessara Therapeutics, Psylo, and the University of Sydney are ... |
| 05.06.2024 | Psylo's Revolutionary Approach to Mental Health Treatment Leading the Way in Biotechnology Innovation | Psylo, a cutting-edge biotechnology company headquartered in San Diego, California, is making significant strides in the realm of mental health treatment with their groundbreaking approach to developing next-generation neuroplastogens. Rece... |
| 03.06.2024 | Psylo Raises $8M in Seed Funding | Psylo, a San Diego, CA-based biotechnology company focused on the development of next-generation neuroplastogens, raised $8M in Seed funding. The round was led by Tenmile, with participation from Palo Santo, Focalpoint Ventures (formerly Em... |
| 03.06.2024 | Psylo Announces First Close on $8 Million Series Seed Financing to Advance Next-Generation Neuroplastogens at BIO Conference in San Diego | Innovative biotech company pioneers PSYLO-100X, a non-hallucinogenic neuroplastogen with promising therapeutic potential SAN DIEGO, June 3, 2024 /PRNewswire/ -- Psylo, a leading biotechnology company focused on the development of next-gener... |
| 22.06.2023 | PSYLO ANNOUNCES SPONSORED RESEARCH AGREEMENT WITH DAIICHI SANKYO TO DEVELOP NON-HALLUCINOGENIC PSYCHIATRIC THERAPIES | The Sponsored Research Agreement will help advance antidepressant treatments for patients in need SYDNEY, June 22, 2023 /PRNewswire/ -- Biotech start-up, Psylo, announced today that it has entered into a Sponsored Research Agreement with gl... |
| 27.10.2022 | Six Aussie startups that raised $56 million this week | It’s been a huge week for Australian startup raises, with more than $56 million invested into six companies, while Square Peg also banked $860 million for two new funds. Psylo: $5 million Biotech startup Psylo has raised $5 million in seed ... |
| - | Psylo | “Psylo is a biotechnology company developing next-generation serotonergic treatments for psychiatric and neurological conditions” |